Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to...
Pharmaceutical
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development,...
Icosavax to Participate in the Jefferies London Healthcare Conference
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)...
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
DEA’s Disregard: Unraveling the Delays in MMJ’s Medical Marijuana Research of Suffering Law Enforcement Patients
DEA'S MANDATE IS DRUG DIVERSION, SECURITY AND TO FACILITATE DRUG DEVELOPMENT?DEA DIRECTOR ANNE MILGRAM THINKS DIFFERENTLY. LAW ENFORCEMENT OFFICERS SUFFER.WASHINGTON,...
Nemysis Limited Announces a Strategic Alliance With Bruno Farmaceutici S.p.A.
DUBLIN, IRELAND / ACCESSWIRE / November 8, 2023 / Nemysis is pleased to announce that it has entered into a...
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.PALO...
Masimo Announces New Member of the Board of Directors
Rolf A. Classon Joins Masimo’s Board of DirectorsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been...
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30...
FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis
TORONTO, ON / ACCESSWIRE / November 7, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Model N Responds to Mounting Regulatory Pharma Pressures with Innovations that Ensure Compliance and Optimize Revenue
340B, Inflation Reduction Act, and global pricing innovations help leading life sciences companies manage regulatory, compliance, and discounting challengesSAN MATEO,...
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBioMENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio,...
Glaukos Announces Participation in Stifel Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the...
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
Click here to register for webinarSAN FRANCISCO, CA / ACCESSWIRE / November 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar...
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one...
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
TARRYTOWN, NY / ACCESSWIRE / November 7, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for...
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE...
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and...
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025...